Clinical Trials Browser

Phase 3 × INDUSTRY × netupitant, palosentron drug combination × Clear all

NCT03403712 2020-06-01

A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

Phase 3 Completed

404 enrolled 19 charts

Vomiting

NCT01339260 2014-11-26

An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

Phase 3 Completed

1,455 enrolled 11 charts

Vomiting